3.2. Everolimus (mTOR Inhibitor) and Trametinib (MEK Inhibitor) Enhance the Efficacy of Neratinib in Both TNBC and HER2+ Breast Cancer Cell Lines. This evidence concerns the gene MAP2K7 and breast carcinoma.